Design Therapeutics, Inc. (DSGN) Ownership
DSGN ownership summary
as of October 18, 2026- Institutions
- 78.7% of shares outstanding
- Insiders
- 31.87% of shares outstanding
- Shares outstanding
- 62.6M
- Float
- 36.2M shares available to trade
- Short interest
- 14.00% 6.6M shares short
- Days to cover
- 8.67 short interest up 21.1% vs prior month
- Institutions 78.72%
- Insiders 31.87%
DSGN top institutional holders
20 largest| # | Holder | % of shares | Shares | Value | Change | Reported |
|---|---|---|---|---|---|---|
| 1 | SR ONE CAPITAL MANAGEMENT, LP | 10.43% | 6.5M | $67.3M | — | June 30, 2026 |
| 2 | Logos Global Management LP | 4.79% | 3.0M | $30.9M | +1.1M (+53.8%) | June 30, 2026 |
| 3 | Baker Bros Advisors LP | 4.28% | 2.7M | $27.6M | +92,452 (+3.6%) | June 30, 2026 |
| 4 | Driehaus Capital Management LLC | 4.25% | 2.7M | $27.4M | +916,128 (+52.5%) | June 30, 2026 |
| 5 | BlackRock Inc | 4.25% | 2.7M | $27.4M | +526,260 (+24.7%) | June 30, 2026 |
| 6 | Point72 Asset Management, L.P. | 3.78% | 2.4M | $24.4M | −356,301 (−13.1%) | June 30, 2026 |
| 7 | Trails Edge Capital Partners, LP | 3.20% | 2.0M | $20.6M | +1.1M (+134.9%) | June 30, 2026 |
| 8 | Frazier Life Sciences Management, L.P. | 2.89% | 1.8M | $18.7M | +1.8M (0.0%) | June 30, 2026 |
| 9 | Vivo Capital, LLC | 2.58% | 1.6M | $16.6M | — | June 30, 2026 |
| 10 | Vanguard Capital Management, LLC | 2.51% | 1.6M | $16.2M | +221,172 (+16.4%) | June 30, 2026 |
| 11 | Caption Management, LLC | 1.79% | 1.1M | $11.5M | +1.0M (+1,189.5%) | June 30, 2026 |
| 12 | Almitas Capital LLC | 1.64% | 1.0M | $10.6M | −503,442 (−32.9%) | June 30, 2026 |
| 13 | Geode Capital Management, LLC | 1.53% | 958K | $9.9M | +265,899 (+38.4%) | June 30, 2026 |
| 14 | Sofinnova Ventures | 1.38% | 865K | $8.9M | +865,135 (0.0%) | June 30, 2026 |
| 15 | FMR Inc | 1.24% | 776K | $8.0M | −21,949 (−2.7%) | June 30, 2026 |
| 16 | Morgan Stanley - Brokerage Accounts | 1.22% | 765K | $7.9M | +108,860 (+16.6%) | June 30, 2026 |
| 17 | State Street Corp | 1.18% | 736K | $7.6M | +76,646 (+11.6%) | June 30, 2026 |
| 18 | Woodline Partners LP | 1.12% | 700K | $7.2M | −261,147 (−27.2%) | June 30, 2026 |
| 19 | Dimensional Fund Advisors, Inc. | 1.11% | 695K | $7.2M | +262,903 (+60.9%) | June 30, 2026 |
| 20 | The Goldman Sachs Group Inc | 1.05% | 657K | $6.8M | +151,866 (+30.1%) | June 30, 2026 |
Value at the latest close. Change = shares bought or sold in the latest quarterly filing (13F). In the top 20, 14 holders added 8.5M shares and 4 cut 1.1M.
DSGN top mutual fund and ETF holders
20 largest| # | Holder | % of shares | Shares | Value | Change | Reported |
|---|---|---|---|---|---|---|
| 1 | Vanguard MStar Total Stk Mkt Idx Invest | 1.86% | 1.2M | $12.0M | — | August 31, 2026 |
| 2 | State Street® SPDR® S&P® Biotech ETF | 1.50% | 941K | $9.7M | −18,000 (−1.9%) | September 30, 2026 |
| 3 | iShares Russell 2000 ETF | 1.31% | 821K | $8.5M | −9,472 (−1.1%) | September 30, 2026 |
| 4 | Fidelity Select Biotechnology | 0.85% | 535K | $5.5M | — | August 31, 2026 |
| 5 | Heptagon Driehaus US Micro Cap Eq C$ Acc | 0.74% | 460K | $4.7M | — | August 31, 2026 |
| 6 | Fidelity Small Cap Index | 0.54% | 337K | $3.5M | +3,521 (+1.1%) | July 31, 2026 |
| 7 | iShares Russell 2000 Growth ETF | 0.47% | 292K | $3.0M | −369 (−0.1%) | September 30, 2026 |
| 8 | iShares Biotechnology ETF | 0.43% | 269K | $2.8M | −2,040 (−0.8%) | September 30, 2026 |
| 9 | Fidelity Enhanced Small Cap Core ETF | 0.39% | 244K | $2.5M | +510 (+0.2%) | September 30, 2026 |
| 10 | Schwab US Small-Cap ETF™ | 0.33% | 205K | $2.1M | +135 (+0.1%) | September 30, 2026 |
| 11 | AZ Fd 1 - AZ Eq - Amer Opps A-EUR Acc | 0.31% | 195K | $2.0M | +194,758 (0.0%) | July 31, 2026 |
| 12 | Driehaus Micro Cap Growth USD | 0.29% | 184K | $1.9M | +49,067 (+36.3%) | July 31, 2026 |
| 13 | Vanguard Russell 2000 ETF | 0.28% | 177K | $1.8M | +4,238 (+2.5%) | August 31, 2026 |
| 14 | Fidelity Extended Market Index | 0.25% | 159K | $1.6M | −857 (−0.5%) | August 31, 2026 |
| 15 | Dimensional US Small Cap ETF | 0.25% | 156K | $1.6M | — | September 30, 2026 |
| 16 | DFA US Small Cap I | 0.22% | 136K | $1.4M | — | August 31, 2026 |
| 17 | North Square Dynamic Small Cap I | 0.20% | 127K | $1.3M | −18,000 (−12.4%) | June 30, 2026 |
| 18 | DFA US Micro Cap I | 0.19% | 118K | $1.2M | +4,325 (+3.8%) | August 31, 2026 |
| 19 | iShares Genomics Immnlgy & Hlthcr ETF | 0.16% | 101K | $1.0M | +2,772 (+2.8%) | September 30, 2026 |
| 20 | iShares Micro-Cap ETF | 0.16% | 97K | $1.0M | −669 (−0.7%) | September 30, 2026 |
Funds report holdings monthly or quarterly; dates differ by fund.
DSGN insider transactions
latest 6| Date | Name | Transaction | Price | Shares | Value |
|---|---|---|---|---|---|
| 2024-12-18 | Deepa Prasad | Sell | $6.27 | 3,806 | $23,864 |
| 2024-08-09 | Arsani William | Sell | $4.25 | 814,874 | $3.5M |
| 2024-03-25 | John P Schmid | Buy | $3.74 | 17,809 | $66,606 |
| 2024-03-22 | John P Schmid | Buy | $3.62 | 9,156 | $33,145 |
| 2023-09-29 | Rodney W Lappe | Buy | $2.35 | 21,000 | $49,350 |
| 2023-08-29 | Deepa Prasad | Buy | $2.31 | 12,000 | $27,720 |
Reported trades by company officers, directors and other filers (including disclosures by members of Congress where EODHD lists them). "—" where the filing gives no share count.
DSGN shares outstanding
Year-end shares outstanding, adjusted for splits.
Who owns DSGN
Institutional investors own 78.7% of Design Therapeutics's shares and insiders 31.87%. The largest holder is SR ONE CAPITAL MANAGEMENT, LP with 10.43% of the shares (6.5M), as of June 30, 2026. Among the top 20 institutions, 14 added shares and 4 reduced their stake in the latest filings. Short interest is 14.00% of the float, or 8.67 days of average trading volume. The share count rose 110.8% since 2020.
Related: DSGN analyst forecast, DSGN key metrics. See the DSGN stock overview for the latest quote and news.
DSGN ownership FAQ
Who owns the most Design Therapeutics stock?
The largest shareholders of Design Therapeutics are SR ONE CAPITAL MANAGEMENT, LP (10.43%), Logos Global Management LP (4.79%), Baker Bros Advisors LP (4.28%), Driehaus Capital Management LLC (4.25%), BlackRock Inc (4.25%).
What percentage of Design Therapeutics is owned by institutions?
Institutions hold 78.7% of Design Therapeutics's shares outstanding; insiders hold 31.87%.
Which funds own Design Therapeutics?
The largest fund holders of Design Therapeutics are Vanguard MStar Total Stk Mkt Idx Invest (1.86%), State Street® SPDR® S&P® Biotech ETF (1.50%), iShares Russell 2000 ETF (1.31%), Fidelity Select Biotechnology (0.85%), Heptagon Driehaus US Micro Cap Eq C$ Acc (0.74%).
What is Design Therapeutics's short interest?
6.6M shares of Design Therapeutics were sold short, 14.00% of the float; at the average daily volume it would take 8.67 days to cover.
Are insiders buying or selling Design Therapeutics?
Of the latest 6 reported insider transactions in Design Therapeutics (since August 29, 2023), 4 were purchases and 2 were sales.
How many shares of Design Therapeutics are outstanding?
Design Therapeutics has 62.6M shares outstanding, of which 36.2M are in the public float.